Black Diamond appointed Melanie Morrison as Senior Vice President, Development Operations, who joined the Company with over two decades of experience in clinical operations, program management, product leadership and other key development functions and in driving corporate transitions from early to late-stage development at several biopharmaceutical companies. Prior to joining Black Diamond, Ms. Morrison served as Senior Vice President, Clinical Operations and Program Management at Nuvation Bio Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 USD | -9.48% | -12.21% | +117.44% |
May. 09 | Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Black Diamond Therapeutics, Inc. Announces Board and Committee Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+117.44% | 321M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BDTX Stock
- News Black Diamond Therapeutics, Inc.
- Black Diamond Therapeutics, Inc. Appoints as Melanie Morrison as Senior Vice President, Development Operations